ADCT Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-0.510.0% YoY
Profit margin-121.8%HEALTHCARE
Market cap$137.9MMicro cap
Wall Street coverage
$3.33median target· current $1.13 (+196.3%)5 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 3.42
- P/S (TTM)
- 1.73
- EV/EBITDA
- -1.43
Profitability & growth
- ROE (TTM)
- -706.0%
- Operating margin
- -118.1%
- Revenue growth YoY
- 2.2%
- Dividend yield
- —
- Beta
- 1.85
Last earnings
Aug 13, 2026 · Estimate $-0.19 · Reported $-0.11
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About ADC Therapeutics SA
Company profileADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Classification
- Sector
- Healthcare
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- BIOPOLE, EPALINGES, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$137.9M
Shares outstanding$127.7M
52W high$4.98
52W low$0.78
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent